BRIEF-Shanghai Bao Pharmaceuticals Says U.S. FDA Approves IND For Subcutaneous Infusion Of BJ007 For Injection

June 10 (Reuters) - Shanghai Bao Pharmaceuticals Co Ltd 2659.HK:

  • U.S. FDA APPROVES IND FOR SUBCUTANEOUS INFUSION OF BJ007 FOR INJECTION ON MAY 27, 2026


Further company coverage: 2659.HK


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.